AbbVie $ABBV flunked a clinical trial study and now the stock is unmasked. The bearishness will end. $ABBV, AbbVie Inc. / H1 ABBV stock will rebound back to $120.Agree or disagree?Login now to vote. Comment below if you have another biotech pick.